CoChat
Sign Up
Cited by 338

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

PCSK9 inhibitors: clinical evidence and implementation

Sabatine, Marc S.·2019·Nature Reviews Cardiology
DOI 10.1038/s41569-018-0107-8
Open this paper in CoChat — free account

Abstract

The gene encoding PCSK9 was first identified and linked to the phenotype of familial hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C) and a reduced risk of coronary artery disease. With amazing rapidity, monoclonal antibodies against PCSK9 were developed and studied in large clinical programmes. These PCSK9 inhibitors lowered plasma LDL-C levels by approximately 60%, even in patients already receiving maximum-dose statin therapy. In the past year, three cardiovascular outcome trials were completed and showed that PCSK9 inhibitors significantly reduce the risk of major vascular events. Reassuringly, this benefit comes with no major offsetting adverse events, such as an excess of myalgias, elevation of hepatic aminotransferases levels in the plasma, incident diabetes mellitus or neurocognitive adverse events. The clinical benefit of PCSK9 inhibitors seen in these trials occurred in the setting of reducing LDL-C levels to unprecedentedly low levels, suggesting that more aggressive LDL-C targets should be adopted. New technologies to inhibit PCSK9 are now being harnessed and might further revolutionize our treatment of dyslipidaemia.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41569-018-0107-8

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. Varret, M. et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. 64, 1378–1387 (1999). · DOI
  2. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154–156 (2003). · DOI · Paper page
  3. Horton, J. D., Cohen, J. C. & Hobbs, H. H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50, S172–S177 (2009). · DOI · Paper page
  4. Maxwell, K. N. & Breslow, J. L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl Acad. Sci. USA 101, 7100–7105 (2004). · DOI · Paper page
  5. Maxwell, K. N., Fisher, E. A. & Breslow, J. L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl Acad. Sci. USA 102, 2069–2074 (2005). · DOI · Paper page
  6. Wasserman, S. et al. Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications. J. Cardiovasc. Pharmacol. Ther. 23, 423–432 (2018). · DOI
  7. Koren, M. J. et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2531–2540 (2014). · DOI · Paper page
  8. Robinson, J. G. et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311, 1870–1882 (2014). · DOI · Paper page
  9. Stroes, E. et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2541–2548 (2014). · DOI · Paper page
  10. Nissen, S. E. et al. Efficacy and tolerability of evolocumab versus ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315, 1580–1590 (2016). · DOI · Paper page
  11. Stein, E. A. et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur. Heart J. 35, 2249–2259 (2014). · DOI · Paper page
  12. Desai, N. R. et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol. 2, 556–560 (2017). · DOI
  13. Raal, F. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet 385, 341–350 (2015). · DOI
  14. Raal, F. J. et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 5, 280–290 (2017). · DOI
  15. Roth, E. M. et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int. J. Cardiol. 176, 55–61 (2014). · DOI
  16. Cannon, C. P. et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J. 36, 1186–1194 (2015). · DOI
  17. Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489–1499 (2015). · DOI · Paper page
  18. Roth, E. M. et al. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis 254, 254–262 (2016). · DOI
  19. Kastelein, J. J. et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36, 2996–3003 (2015).
  20. Ginsberg, H. N. et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther. 30, 473–483 (2016). · DOI
  21. Hartgers, M. L. et al. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. J. Clin. Lipidol. 12, 390–396.e8 (2018). · DOI
  22. Desai, N. R. et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128, 962–969 (2013). · DOI
  23. Sabatine, M. S. et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am. Heart J. 173, 94–101 (2016). · DOI · Paper page
  24. Wiviott, S. D. The effects of adding the CETP inhibitor anacetrapib to statin on urgent and routine revascularization: results from the HPS 3/TIMI 55-REVEAL trial. J. Am. Coll. Cardiol. 71, A107 (2018). · DOI
  25. Giugliano, R. P. et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol. 2, 1385–1391 (2017). · DOI
  26. Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P. & Glynn, R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565–571 (2012). · DOI · Paper page
  27. Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 5, 941–950 (2017). · DOI · Paper page
  28. Giugliano, R. P. et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy — a cognitive study of patients enrolled in the FOURIER trial. Clin. Cardiol. 40, 59–65 (2017). · DOI
  29. Ridker, P. M. et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) lipid lowering and SPIRE cardiovascular outcomes trials. Am. Heart J. 178, 135–144 (2016). · DOI
  30. Schwartz, G. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am. Heart J. 168, 682–689 (2014). · DOI · Paper page
  31. Wiviott, S. D. et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 113, 1406–1414 (2006). · DOI
  32. Ference, B. A. et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur. Heart J. 39, 2540–2545 (2018). · DOI · Paper page
  33. Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001–1009 (1996). · DOI · Paper page
  34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
  35. Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390, 1962–1971 (2017). · DOI · Paper page
  36. Kazi, D. S. et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316, 743–753 (2016). · DOI · Paper page
  37. Kazi, D. S. et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318, 748–750 (2017). · DOI
  38. Fonarow, G. C. et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2, 1069–1078 (2017). · DOI
  39. Sabatine, M. S. & Giugliano, R. P. Low-density lipoprotein cholesterol treatment in the proprotein convertase subtilisin/kexin type 9 inhibitor era: getting back on target. JAMA Cardiol. 2, 935–936 (2017). · DOI
  40. Sabatine, M. S., Wiviott, S. D., Im, K. A., Murphy, S. A. & Giugliano, R. P. Efficacy and safety of LDL-cholesterol lowering in patient populations starting with low LDL-cholesterol — a meta-analysis. JAMA Cardiol. 3, 823–828 (2018). · DOI
  41. Bonaca, M. P. et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J. Am. Coll. Cardiol. 70, 1368–1375 (2017). · DOI
  42. Dellborg, M. et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur. Heart J. 38, P3670 (2017). · DOI
  43. Bansilal, S. et al. Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease. J. Am. Coll. Cardiol. 71, 489–496 (2018). · DOI
  44. Bonaca, M. P. et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 137, 338–350 (2018). · DOI · Paper page
  45. Landlinger, C. et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur. Heart J. 38, 2499–2507 (2017). · DOI
  46. Pan, Y. et al. A therapeutic peptide vaccine against PCSK9. Sci. Rep. 7, 12534 (2017). · DOI
  47. Wang, X. et al. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo — brief report. Arterioscler. Thromb. Vasc. Biol. 36, 783–786 (2016). · DOI
  48. Ding, Q. et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 115, 488–492 (2014). · DOI · Paper page
  49. Thakore, P. I. et al. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat. Commun. 9, 1674 (2018). · DOI

Cited by

Sorted by citations

Metadata

Authors
Sabatine, M. S.
Venue
Nature Reviews Cardiology
Publisher
Springer Science and Business Media LLC
Published
2018-11-12
Volume
16
Issue
3
Pages
155-165
ISSN
  • 1759-5002
  • 1759-5010
DOI
10.1038/s41569-018-0107-8
Cited by
338
References
25
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review